GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Achiko AG (XSWX:ACHI) » Definitions » Momentum Rank

Achiko AG (XSWX:ACHI) Momentum Rank : 0 (As of Jun. 09, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Achiko AG Momentum Rank?

Achiko AG has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Achiko AG Momentum Rank Related Terms

Thank you for viewing the detailed overview of Achiko AG's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Achiko AG (XSWX:ACHI) Business Description

Traded in Other Exchanges
N/A
Address
Tessinerplatz 7, Zurich, CHE, CH-8002
Achiko AG is developing disruptive diagnostic solutions that put people first. The company product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX, and companion health apps via its digital mobile health technology division, Teman Sehat. The AptameX DNA aptamer tests can be rapidly chemically synthesized, are cost-effective, and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate, and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.

Achiko AG (XSWX:ACHI) Headlines

No Headlines